SU-E-T-222: Performance Comparison of In-Vivo Dosimeters, including TLDs, MOSFETs, and OSLDs for Patients Receiving Total Body Irradiation

2011 ◽  
Vol 38 (6Part13) ◽  
pp. 3537-3537
Author(s):  
S Pillai ◽  
W Laub ◽  
T He
2009 ◽  
Vol 36 (6Part12) ◽  
pp. 2580-2580 ◽  
Author(s):  
C Esquivel ◽  
M Smith ◽  
S Stathakis ◽  
A Gutiérrez ◽  
C Shi ◽  
...  

2013 ◽  
Vol 40 (6Part11) ◽  
pp. 223-223 ◽  
Author(s):  
C Holloway ◽  
S Mahendra ◽  
D Kaurin ◽  
L Sweeney

Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4565-4565
Author(s):  
Sebastian Giebel ◽  
Leszek Miszczyk ◽  
Krzysztof Slosarek ◽  
Leila Moukhtari ◽  
Fabio Ciceri ◽  
...  

Background Total body irradiation (TBI) is widely used for conditioning prior to both allogeneic and autologous hematopoietic stem cell transplantation. Myeloablatitve doses of TBI are considered highly effective but also associated with relevant toxicity. Both, the efficacy and toxicity may depend on many methodological aspects of TBI. The goal of the survey was to explore current practice across centers collaborating in the European Group for Blood and Marrow Transplantation (EBMT). Methods The questionnaire sent to all EBMT centers included 19 questions regarding the doses used for myeloabaltive TBI, the way of fractionation, the modes of delivering the dose, type of immobilization, methods of dosimetry and organ shielding. 56 centers from 23 countries responded. Results All centers differ with regard at least one of the methodological aspects. The total dose of TBI used for myeloablative transplantation ranges from 8 to 14.4 Gy, the number of fractions ranges from 1 to 8, while the dose per fraction is 1.65 – 8 Gy. Altogether 16 modalities of dosing/fractionation have been identified with 6 x 2 Gy being the most frequent one (n=36, 64%). The dose rate in the axis of the beam ranges from 4.5 – 30 cGy/min (27 modalities; most frequently 18 cGy/min, 5%). The treatment unit is regular linac (n=51, 91%) or cobalt unit (n=5, 9%). Beams used for regular linac are 6 to 23 MV (most frequently 6 MV, n=26, 51%). The most frequent technique used for irradiation is “patient in one field” using two fields per fraction and two patient positions per fraction (n=36, 64%), however, altogether 11 modalities were described with regard to the technique, number of fields and positions per fraction. Source to surface distance is 2 to 5 m (most frequently 4 m; n=10, 18%). In 23 (41%) centers patients are immobilized during TBI, using 9 different types of device. Fifty-two centers (93%) measure acquired dose of irradiation using 5 types of detectors for in vivo dosimetry (most frequently semiconductors; n=37, 66%). Accepted discrepancy between planned and measured dose ranges from 1.5 to 10%. In 47 (84%) centers lungs are shielded during irradiation and lung density is considered for treatment planning. Maximum accepted dose for lungs ranges from 6 to 12 Gy. Additionally, in some centers lenses (14%), thyroid gland (7%), larynx (4%), kidneys (4%) and/or salivary glands (2%) are shielded. Conclusions TBI is an extremely heterogeneous treatment modality. Differences between centers regard all methodological aspects. Our findings should warrant caution in interpretation of clinical studies involving TBI. Further investigation is needed to evaluate whether differences between treatment modalities influence the efficacy and safety of the TBI procedure. Finally, efforts to standardize the method should be considered. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 119 (25) ◽  
pp. 6155-6161 ◽  
Author(s):  
Paul Veys ◽  
Robert F. Wynn ◽  
Kwang Woo Ahn ◽  
Sujith Samarasinghe ◽  
Wensheng He ◽  
...  

AbstractTo determine whether in vivo T-cell depletion, which lowers GVHD, abrogates the antileukemic benefits of myeloablative total body irradiation–based conditioning and unrelated donor transplantation, in the present study, we analyzed 715 children with acute lymphoblastic leukemia. Patients were grouped for analysis according to whether conditioning included antithymocyte globulin (ATG; n = 191) or alemtuzumab (n = 132) and no in vivo T-cell depletion (n = 392). The median follow-up time was 3.5 years for the ATG group and 5 years for the alemtuzumab and T cell–replete groups. Using Cox regression analysis, we compared transplantation outcomes between groups. Compared with no T-cell depletion, grade 2-4 acute and chronic GVHD rates were significantly lower after in vivo T-cell depletion with ATG (relative risk [RR] = 0.66; P = .005 and RR = 0.55; P < .0001, respectively) or alemtuzumab (RR = 0.09; P < .003 and RR = 0.21; P < .0001, respectively). Despite lower GVHD rates after in vivo T-cell depletion, nonrelapse mortality, relapse, overall survival, and leukemia-free survival (LFS) did not differ significantly among the treatment groups. The 3-year probabilities of LFS after ATG-containing, alemtuzumab-containing, and T cell–replete transplantations were 43%, 49%, and 46%, respectively. These data suggest that in vivo T-cell depletion lowers GVHD without compromising LFS among children with acute lymphoblastic leukemia who are undergoing unrelated donor transplantation with myeloablative total body irradiation–based regimens.


2021 ◽  
Vol 12 ◽  
Author(s):  
Kimberly J. Jurgensen ◽  
William K. J. Skinner ◽  
Bryan Oronsky ◽  
Nacer D. Abrouk ◽  
Andrew E. Graff ◽  
...  

The present studies evaluate the in vivo prophylactic radioprotective effects of 1-bromoacetyl-3, 3-dinitroazetidine (RRx-001), a phase III anticancer agent that inhibits c-myc and downregulates CD-47, after total body irradiation (TBI), in lethally and sublethally irradiated CD2F1 male mice. A single dose of RRx-001 was administered by intraperitoneal (IP) injection 24 h prior to a lethal or sublethal radiation dose. When irradiated with 9.35 Gy, the dose lethal to 70% of untreated mice at 30 days (LD70/30), only 33% of mice receiving RRx-001 (10 mg/kg) 24 h prior to total body irradiation (TBI) died by day 30, compared to 67% in vehicle-treated mice. The same pretreatment dose of RRx-001 resulted in a significant dose reduction factor of 1.07. In sublethally TBI mice, bone marrow cellularity was increased at day 14 in the RRx-001-treated mice compared to irradiated vehicle-treated animals. In addition, significantly higher numbers of lymphocytes, platelets, percent hematocrit and percent reticulocytes were observed on days 7 and/or 14 in RRx-001-treated mice. These experiments provide proof of principle that systemic administration of RRx-001 prior to TBI significantly improves overall survival and bone marrow regeneration.


2005 ◽  
Vol 32 (6Part9) ◽  
pp. 1996-1996 ◽  
Author(s):  
TM Briere ◽  
RC Tailor ◽  
NB Tolani ◽  
KL Prado ◽  
RG Lane ◽  
...  

1989 ◽  
Vol 16 (1) ◽  
pp. 165-170 ◽  
Author(s):  
Rong-Nian Shen ◽  
Ned B. Hornback ◽  
Li Lu ◽  
Li T. Chen ◽  
Zacharie Brahmi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document